GlassScriptPhysician profile
Tracy D Pena
NPI 1760747943
$13,756.46
in general payments reported to CMS, 2019-2025
41 companies · $1,180 in 2025
The $1,180 reported for 2025 was more than what 88% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,465 · 2022: $2,987 · 2023: $2,996 · 2024: $3,128 · 2025: $1,180.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,271 · Education: $33.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,271.42 |
| Education | $33.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $3,222.49 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,897.75 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $1,458.57 | 2021-2025 | |
| Pfizer INC. | $743.12 | 2021-2025 | |
| Amgen INC. | $731.37 | 2021-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $634.05 | 2021-2025 | Jardiance, Tradjenta, Synjardy |
| Bayer Healthcare Pharmaceuticals INC. | $487.33 | 2023-2025 | |
| Amarin Pharma, INC. | $434.28 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $401.58 | 2021-2024 | Airsupra, Farxiga, Breztri |
| Esperion Therapeutics, INC. | $359.86 | 2021-2023 | Nexletol |
| Glaxosmithkline, LLC. | $312.18 | 2021-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $298.64 | 2021-2025 | Xifaxan, Trulance |
| Dexcom, INC. | $273.90 | 2021-2025 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $228.82 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $217.62 | 2021-2023 | Belsomra, Steglatro, Steglujan |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tracy Pena listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.